Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study

INTRODUCTION: OnabotulinumtoxinA (BT-A) quarterly was the first treatment approved specifically for chronic migraine (CM). It is unclear whether three cycles are better than two to assess early BT-A response. METHODS: We performed a retrospective analysis on real-life prospectively collected data in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ornello, Raffaele, Ahmed, Fayyaz, Negro, Andrea, Miscio, Anna Maria, Santoro, Antonio, Alpuente, Alicia, Russo, Antonio, Silvestro, Marcello, Cevoli, Sabina, Brunelli, Nicoletta, Vernieri, Fabrizio, Grazzi, Licia, Baraldi, Carlo, Guerzoni, Simona, Andreou, Anna P., Lambru, Giorgio, Frattale, Ilaria, Kamm, Katharina, Ruscheweyh, Ruth, Russo, Marco, Torelli, Paola, Filatova, Elena, Latysheva, Nina, Gryglas-Dworak, Anna, Straburzynski, Marcin, Butera, Calogera, Colombo, Bruno, Filippi, Massimo, Pozo-Rosich, Patricia, Martelletti, Paolo, Sacco, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119503/
https://www.ncbi.nlm.nih.gov/pubmed/33778933
http://dx.doi.org/10.1007/s40122-021-00253-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119503/
https://www.ncbi.nlm.nih.gov/pubmed/33778933
http://dx.doi.org/10.1007/s40122-021-00253-0

Ejemplares similares